Ray Therapeutics
Phase 2/3We use the innovative technology of optogenetics to reprogram surviving neurons in the retina of the eye to sense light and send visual signals to the brain—restoring vision.
Founded
2019
Focus
RNA & Gene Therapy
About
We use the innovative technology of optogenetics to reprogram surviving neurons in the retina of the eye to sense light and send visual signals to the brain—restoring vision.
Funding History
2Total raised: $175M
Series A$75MMubadala CapitalJan 15, 2024
Seed$100MMubadala CapitalApr 15, 2023
Company Info
TypePrivate
Founded2019
LocationSan Francisco, United States
StagePhase 2/3
Contact
SIMILAR COMPANIES
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
Pre-clinical · Cambridge
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile